ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.048,62
-0,85%
S&P 500
5.827,04
-1,54%
Dow Jones
41.938,45
-1,63%
Euro vs US Dollar
1,01879
-0,55%
Bitcoin
91.069,96
-3,62%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Cocrystal Pharma Inc (COCP)

  7. Cocrystal Pharma Inc (COCP) News

COCP

Cocrystal Pharma (COCP)

Cocrystal Pharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:COCP
DatumZeitQuelleÜberschriftSymbolFirma
08/01/202514h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
08/01/202514h00GlobeNewswire Inc.Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral InfectionsNASDAQ:COCPCocrystal Pharma Inc
31/12/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
31/12/202414h00GlobeNewswire Inc.Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344NASDAQ:COCPCocrystal Pharma Inc
13/11/202421h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
13/11/202414h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
13/11/202414h00GlobeNewswire Inc.Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
31/10/202414h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
31/10/202413h00GlobeNewswire Inc.Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season BeginsNASDAQ:COCPCocrystal Pharma Inc
11/10/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COCPCocrystal Pharma Inc
11/10/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COCPCocrystal Pharma Inc
11/10/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COCPCocrystal Pharma Inc
11/10/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COCPCocrystal Pharma Inc
10/10/202423h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
26/09/202414h00GlobeNewswire Inc.Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose CohortsNASDAQ:COCPCocrystal Pharma Inc
20/08/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
19/08/202422h05GlobeNewswire Inc.Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment ConferencesNASDAQ:COCPCocrystal Pharma Inc
14/08/202414h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
14/08/202414h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
14/08/202414h00GlobeNewswire Inc.Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
18/07/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
18/07/202414h00GlobeNewswire Inc.Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease InhibitorNASDAQ:COCPCocrystal Pharma Inc
20/06/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
20/06/202414h00GlobeNewswire Inc.New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy CowsNASDAQ:COCPCocrystal Pharma Inc
13/05/202414h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
13/05/202414h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
13/05/202414h00GlobeNewswire Inc.Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
07/05/202422h30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:COCPCocrystal Pharma Inc
01/05/202414h00GlobeNewswire Inc.Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaNASDAQ:COCPCocrystal Pharma Inc
28/03/202413h00GlobeNewswire Inc.Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:COCP

Kürzlich von Ihnen besucht

LSE
61TE
First.abu 24
USOTC
BTGN
Bitcoin Generation (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten